IN8BIO, INC. — Director's Dealing 2021

Jul 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2021-07-29

Reporting Person: Beelen Melissa (VP, Clinical Operation)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$1.0685	2029-04-16	Common Stock (39184)		Direct
Employee Stock Option (right to buy)	$1.2329	2030-05-04	Common Stock (13140)		Direct
Employee Stock Option (right to buy)	$6.7398	2030-10-04	Common Stock (57434)		Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to the option vested on April 1, 2020, and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F2: Twenty-five percent (25%) of the shares subject to the option shall vest on June 1, 2021, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F3: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2021, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.